Abstract:Abstract Enhancer of zeste homolog 2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which, in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog(SUZ12), regulates cell lineage determination and homeostasis. Enzymatic hyperactivity of EZH2 has been linked to aberrant repression of tumor suppressor genes in diverse cancers. Here, we report the development of stabilized a-helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-responsively disrupting the EZH2-EED complex and reducing EZH2 protein levels, a mechanism distinct from that reported for small-molecule EZH2 inhibitors targeting the enzyme catalytic domain. The essential α-helical domain of EZH2 (residues 40-68) that engages EED established the basis for designing hydrocarbon-stapled derivatives to disrupt the specific protein interaction. Non-natural amino acids with olefinic side chains were substituted at (i, i + 4) positions within the EZH2 α-helical sequence, followed by ruthenium-catalyzed olefin metathesis, to yield SAH-EZH2 peptides. Our lead, cell-permeable analog effectively targeted EED in situ, dissociated the EZH2-EED complex and impaired the function of PRC2, as reflected by reduction of the H3K27me3 and EZH2 protein levels, and increased expression of PRC2-regulated cell differentiation marker genes. In response to SAH-EZH2 treatment, murine MLL-AF9 leukemia cells, which are PRC2-dependent, manifested growth arrest and monocyte-macrophage differentiation, in accordance with the phenotypic consequences of shRNA-mediated reduction of EZH2 (or EED) or genetic ablation of Ezh2 (or Eed). In evaluating SAH-EZH2 activity alongside the small-molecule EZH2 inhibitor GSK126 in a series of B-cell lymphoma lines, we observed sequence-specific antiproliferative responses, transcriptional modulation, cellular specificity and a distinct mechanism of action for SAH-EZH2. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B254. Citation Format: Woojin Kim, Gregory H. Bird, Tobias Neff, Guoji Guo, Marc A. Kerenyi, Loren D. Walensky, Stuart H. Orkin. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B254.

Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics

Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs

Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders

EED-mediated Histone Methylation is Critical for CNS Myelination and Remyelination by Inhibiting WNT, BMP, and Senescence Pathways

Abstract LB-A09: EED Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Targeted Disruption of the EZH 2 / EED Complex Inhibits EZH 2-Dependent Cancer

Abstract B254: Targeted Disruption of the EZH2-EED Complex Inhibits EZH2-dependent Cancer.

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma

Discovery of EEDi-5273 As an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Structural Basis of Ezh2 Recognition by Eed

Regulation of Chromosome Regulator EZH2 in Cancer Epigenetics and EZH2 Targeted Drugs in Cancer Therapy

Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors

Rapid Identification of Novel Allosteric PRC2 Inhibitors.

Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy

Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential